QLT to Appoint Glen Ibbott as Interim Chief Financial Officer
dec. 16
QLT Announces Results of Annual General Meeting of Shareholders
Provides Update on Strategic and Business Review
Dec. 5
QLT Announces
Results From Proof-of Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision
dec. 2
QLT Announces Departure of Chief Financial Officer
OCT. 24
QLT Appoints Dr. Geoffrey F. Cox as Interim Chief Executive Officer
Announces 2014 Annual General Meeting Date
2014 Proxy Materials and Annual Report For the 2014 Proxy Statement and Annual Report for the fiscal year ended December 31, 2013, click here
Sept. 13
Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT
HEAD OFFICE: QLT Inc., 887 Great Northern Way, Suite 250, Vancouver, BC, Canada, V5T 4T5 | t 1.877.764.3131
